MLTX vs. ACAD, BHC, MRUS, MOR, TGTX, CORT, FOLD, ARWR, VERA, and INDV
Should you be buying MoonLake Immunotherapeutics stock or one of its competitors? The main competitors of MoonLake Immunotherapeutics include ACADIA Pharmaceuticals (ACAD), Bausch Health Companies (BHC), Merus (MRUS), MorphoSys (MOR), TG Therapeutics (TGTX), Corcept Therapeutics (CORT), Amicus Therapeutics (FOLD), Arrowhead Pharmaceuticals (ARWR), Vera Therapeutics (VERA), and Indivior (INDV). These companies are all part of the "pharmaceutical preparations" industry.
ACADIA Pharmaceuticals (NASDAQ:ACAD) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.
ACADIA Pharmaceuticals has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500.
ACADIA Pharmaceuticals currently has a consensus price target of $28.94, indicating a potential upside of 90.63%. MoonLake Immunotherapeutics has a consensus price target of $74.46, indicating a potential upside of 78.52%. Given MoonLake Immunotherapeutics' higher probable upside, research analysts clearly believe ACADIA Pharmaceuticals is more favorable than MoonLake Immunotherapeutics.
ACADIA Pharmaceuticals received 830 more outperform votes than MoonLake Immunotherapeutics when rated by MarketBeat users. However, 77.05% of users gave MoonLake Immunotherapeutics an outperform vote while only 72.96% of users gave ACADIA Pharmaceuticals an outperform vote.
MoonLake Immunotherapeutics has lower revenue, but higher earnings than ACADIA Pharmaceuticals. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, ACADIA Pharmaceuticals had 26 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 57 mentions for ACADIA Pharmaceuticals and 31 mentions for MoonLake Immunotherapeutics. ACADIA Pharmaceuticals' average media sentiment score of 0.57 beat MoonLake Immunotherapeutics' score of 0.09 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.
MoonLake Immunotherapeutics has a net margin of 0.00% compared to MoonLake Immunotherapeutics' net margin of -0.21%. MoonLake Immunotherapeutics' return on equity of -0.41% beat ACADIA Pharmaceuticals' return on equity.
96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 27.5% of ACADIA Pharmaceuticals shares are held by company insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
ACADIA Pharmaceuticals beats MoonLake Immunotherapeutics on 10 of the 16 factors compared between the two stocks.
Get MoonLake Immunotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MoonLake Immunotherapeutics Competitors List
Related Companies and Tools
